Literature DB >> 583322

Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin.

P Lund-Johansen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 583322      PMCID： PMC1429746     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  11 in total

1.  Haemodynamic long-term effects of beta-receptor-blocking agents in hypertension: a comparison between alprenolol, atenolol, metoprolol and timolol.

Authors:  P Lund-Johansen; O J Ohm
Journal:  Clin Sci Mol Med Suppl       Date:  1976-12

2.  Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise.

Authors:  G Koch
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

3.  Effects of prazosin on renal function and fluid-electrolyte metabolism.

Authors:  M H Maxwell
Journal:  Postgrad Med       Date:  1975-11       Impact factor: 3.840

4.  Haemodynamic long-term effects of atenolol at rest and during exercise in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Hemodynamic long-term effects of timolol at rest and during exercise in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Acta Med Scand       Date:  1976

6.  Effect of timolol versus propranolol on hypertension and hemodynamics.

Authors:  W S Aronow; J Ferlinz; M Del Vicario; K Moorthy; J King; J Cassidy
Journal:  Circulation       Date:  1976-07       Impact factor: 29.690

Review 7.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

8.  Haemodynamic long-term effects of prazosin plus tolamolol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

9.  Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

Authors:  P Lund-Johansen; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

10.  Hemodynamic, reflexive, and metabolic alterations induced by acute and chronic timolol therapy in hypertensive man.

Authors:  F G Dunn; J G de Carvalho; E D Frohlich
Journal:  Circulation       Date:  1978-01       Impact factor: 29.690
View more
  8 in total

1.  Impact of dilevalol on haemodynamic changes during emotional stress.

Authors:  H Rüddel; W Langewitz; M Bähr; M Düsterwald; H Schächinger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

Review 3.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 4.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

7.  Alternatives to beta-blockade in therapy of hypertension with angina pectoris: role of nifedipine or of labetalol.

Authors:  L H Opie; D White; J Lee; W F Lubbe
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 8.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.